High cellular prion protein expression in cholangiocarcinoma: A marker for early postoperative recurrence and unfavorable prognosis

doi:10.4240/wjgs.v17.i3.101940

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-4)

Sum=0

Mar 27, 2025 (publication date) through Feb 24, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Mar 27, 2025; 17(3): 101940
Published online Mar 27, 2025. doi: 10.4240/wjgs.v17.i3.101940

Table 1 Patient and tumor characteristics of the study, n (%)

Characteristics	Category	Subgroup (based on immunostaining)		Total (n = 76)	P value
Characteristics	Category	Low PrP^C (n = 38)	High PrP^C (n = 38)	Total (n = 76)	P value
Age (years), mean ± SD		66.7 ± 9.5	66.8 ± 9.8	66.7 ± 9.6	0.953
Male		22 (57.9)	27 (71.1)	49 (64.5)	0.338
BMI (kg/m²), mean ± SD		24.4 ± 2.9	23.4 ± 2.7	23.9 ± 2.8	0.139
Location	Hilar CCA	22 (57.9)	15 (39.5)	37 (48.7)	0.169
Location	Intrahepatic CCA	16 (42.1)	23 (60.5)	39 (51.3)	0.169
Tumor size (cm), mean ± SD		4.1 ± 1.9	5.3 ± 3.5	4.7 ± 2.8	0.056
Positive LN		17 (44.7)	17 (44.7)	34 (44.7)	1.000
TNM stage	I	6 (15.8)	5 (13.2)	11 (14.5)	0.890
	II	9 (23.7)	8 (21.1)	17 (22.4)
	III	23 (60.5)	25 (65.8)	48 (63.2)
Resection margin	R0	27 (71.1)	21 (55.3)	48 (63.2)	0.262
	R1	11 (28.9)	16 (42.1)	27 (35.5)
	R2	0 (0.0)	1 (2.6)	1 (1.3)
Differentiation	WD	8 (21.1)	12 (31.6)	20 (26.3)	0.177
	MD	25 (65.8)	25 (65.8)	50 (65.8)
	PD	5 (13.2)	1 (2.6)	6 (7.9)
Laboratory tests	CEA (ng/dL)	5.6 ± 4.4	11.1 ± 31.0	8.1 ± 21.0	0.406
Laboratory tests	CA19-9 (U/mL)	813.7 ± 2038.1	1115.9 ± 2461.6	957.8 ± 2237.2	0.591

PrP^C: Cellular prion protein; BMI: Body mass index; LN: Lymph node; TNM: Tumor-node-metastasis; CCA: Cholangiocarcinoma; R0: No cancer cells seen microscopically at the primary tumor site; R1: Cancer cells present microscopically at the primary tumor site; R2: Macroscopic residual tumor at primary cancer site or regional lymph nodes; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; WD: Well-differentiated; MD: Moderately differentiated; PD: Poorly differentiated.

Citation: Shin DW, Cho YA, Moon SH, Kim TH, Park JW, Lee JW, Choe JY, Kim MJ, Kim SE. High cellular prion protein expression in cholangiocarcinoma: A marker for early postoperative recurrence and unfavorable prognosis. World J Gastrointest Surg 2025; 17(3): 101940
URL: https://www.wjgnet.com/1948-9366/full/v17/i3/101940.htm
DOI: https://dx.doi.org/10.4240/wjgs.v17.i3.101940